Peak Frameworks

OCTOBER 30, 2023

It's also why banks are so eager to have deposits; they're the cheapest form of capital for them. These charges were in the spotlight in 2019 when U.S. 2019 was a notable year for trading, especially for banks like J.P. When Facebook went public in 2012, it needed an investment bank to handle the Initial Public Offering (IPO).

Bank 52

Bank Banking Proprietary Trading Investment Banking 52

Cooley M&A

NOVEMBER 1, 2018

government shutdown disrupting the market for IPOs, Brexit uncertainty, natural disasters and various other crises, cross-border M&A activity momentum continues. The following 10 key trends are underpinning hyperactivity in global M&A markets and are set to continue to shape deals well into 2019. corporations following the U.S.

M&A 52

M&A Mergers and Acquisitions Government Business 52

Cooley M&A

SEPTEMBER 16, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. We now turn to the exceptions in dual-class charter transfer provisions that may be available to eliminate this risk.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

The Deal

AUGUST 9, 2023

M&A is a central part of SymphonyAI’s growth strategy as the company prepares for a potential private placement and, eventually, an IPO. “We’re billion market capitalization and trades at 12 times projected sales for the next 12 months, according to FactSet Research Systems Inc. AI), which is not profitable, has a $4.4

M&A 40

M&A Private Equity Retail Financial Services 40

Cooley M&A

JANUARY 10, 2022

As SPAC IPOs broke records – in both value and volume – in 2020 (and again in 2021), it was inevitable that stockholder litigation would follow. SPACs are public companies that raise capital for the express purpose of merging with a private company and taking it public (referred to as the “deSPAC transaction”). III, is no exception.

Shares 40

Shares IPO Mergers IT 40

Cooley M&A

JANUARY 23, 2024

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. In 2023, Tang Capital filed a total of five separate Schedule 13Ds with the SEC seeking to acquire five different companies on similar terms.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Mergers and Inquisitions

APRIL 10, 2024

In Europe, 35% of football clubs have been funded via capital from PE/VC firms, sovereign wealth funds, or private consortiums. A great example is how many European football clubs became distressed during COVID and were forced to seek private capital. The MLB started allowing PE ownership in 2019, and the NHL followed suit in 2021.

Private Equity 103

Private Equity Equities Funds Entertainment 103

Cooley M&A

JANUARY 22, 2021

Although global deal value was a subdued $966 billion in the first half of 2020 (down nearly 50% compared to the first half of 2019), momentum skyrocketed in the second half of the year to nearly $2.2 compared to 2019. compared to 2019, and up even higher (57%) when looking solely at US deal value. COVID-19: The New Normal.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

JANUARY 22, 2021

If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. billion deal inked in 2019 that included more than $2 billion in contingent payments based on the achievement of certain milestones.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. on transactions over 2019’s mega?mergers. These players have looked further afield to add new capabilities and pipeline assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40